Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01597908
First received: May 10, 2012
Last updated: August 14, 2014
Last verified: July 2014
  Purpose

This is a two-arm, open-label, randomised, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy to vemurafenib. Subjects with histologically confirmed cutaneous melanoma that is either stage IIIc (unresectable) or stage IV, and BRAF V600E/K mutation positive will be screened for eligibility. Subjects who have had prior systemic anti-cancer treatment in the advanced or metastatic setting will not be eligible although prior systemic treatment in the adjuvant setting will be allowed. Approximately 694 subjects will be randomised 1:1 (combination therapy:vemurafenib). The primary endpoint is overall survival (OS) for subjects receiving the combination therapy compared with those receiving vemurafenib.


Condition Intervention Phase
Melanoma
Drug: Dabrafenib
Drug: Vemurafenib
Drug: Trametinib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: approx. 20 months ] [ Designated as safety issue: No ]
    time from randomisation until death due to any cause


Secondary Outcome Measures:
  • Progression Free Survival [ Time Frame: approx. 10 months ] [ Designated as safety issue: No ]
    time from randomisation to until the earliest date of disease progression or death due to any cause

  • Overall Response Rate [ Time Frame: approx. 10 months ] [ Designated as safety issue: No ]
    percentage of subjects with a confirmed or unconfirmed completed response (CR) or partial response (PR) at any time per RECIST 1.1

  • Duration of Response [ Time Frame: approx. 10 months ] [ Designated as safety issue: No ]
    time from first documented evidence of CR or PR until disease progression or death due to any cause among subjects who achieve an overall response (i.e., confirmed or unconfirmed CR or PR)


Enrollment: 694
Study Start Date: June 2012
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dabrafenib plus Trametinib
BRAF inhibitor plus MEK inhibitor
Drug: Dabrafenib
dabrafenib 150 mg twice daily po
Drug: Trametinib
trametinib 2 mg once daily po
Active Comparator: Vemurafenib
BRAF inhibitor
Drug: Vemurafenib
vemurafenib 960 mg twice daily po

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • >= 18 years of age
  • Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma
  • Measurable disease according to RECIST 1.1
  • Women of childbearing potential with negative serum pregnancy test prior to randomisation
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Adequate baseline organ function

Exclusion Criteria:

  • Any prior use of a BRAF or MEK inhibitor
  • Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior systemic treatment in the adjuvant setting is allowed
  • History of another malignancy (except subjects who have been disease free for 3 years or with a history of completely resected non-melanoma skin cancer)
  • Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)
  • Brain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for >= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for >= 12 weeks, and are asymptomatic with no corticosteroid requirements for >= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for >= 4 weeks prior to randomisation
  • History or evidence of cardiovascular risk (LVEF < LLN; QTcB >= 480 msec; blood pressure or systolic >=140 mmHg or diastolic >= 90 mmHg which cannot be controlled by anti-hypertensive therapy)
  • History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01597908

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35243
United States, Arizona
GSK Investigational Site
Gilbert, Arizona, United States, 85234
United States, California
GSK Investigational Site
Beverly Hills, California, United States, 90211
GSK Investigational Site
San Francisco, California, United States, 94115
GSK Investigational Site
Vallejo, California, United States, 94589
United States, Colorado
GSK Investigational Site
Aurora, Colorado, United States, 80045
United States, Florida
GSK Investigational Site
Jacksonville, Florida, United States, 32204
GSK Investigational Site
Miami Beach, Florida, United States, 33140
GSK Investigational Site
Orlando, Florida, United States, 32804
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30322
GSK Investigational Site
Atlanta, Georgia, United States, 30341
United States, Iowa
GSK Investigational Site
Iowa City, Iowa, United States, 52242-1009
United States, Michigan
GSK Investigational Site
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
GSK Investigational Site
Fridley, Minnesota, United States, 55432
United States, Missouri
GSK Investigational Site
St. Louis, Missouri, United States, 63110
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89148
United States, New Jersey
GSK Investigational Site
Hackensack, New Jersey, United States, 07601
GSK Investigational Site
New Brunswick, New Jersey, United States, 08901
United States, New York
GSK Investigational Site
New York, New York, United States, 10029
United States, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599-7600
GSK Investigational Site
Charlotte, North Carolina, United States, 28204
GSK Investigational Site
Durham, North Carolina, United States, 27710
United States, Ohio
GSK Investigational Site
Cincinnati, Ohio, United States, 45219
GSK Investigational Site
Columbus, Ohio, United States, 43210
United States, Oregon
GSK Investigational Site
Bend, Oregon, United States, 97701
GSK Investigational Site
Portland, Oregon, United States, 97213
GSK Investigational Site
Portland, Oregon, United States, 97239
United States, South Carolina
GSK Investigational Site
Charleston, South Carolina, United States, 29425
GSK Investigational Site
Greenville, South Carolina, United States, 29605
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37232-6307
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75246
United States, Utah
GSK Investigational Site
Salt Lake City, Utah, United States, 84112-5550
GSK Investigational Site
Salt Lake City, Utah, United States, 84106
United States, Vermont
GSK Investigational Site
Burlington, Vermont, United States, 05403
United States, Virginia
GSK Investigational Site
Charlottesville, Virginia, United States, 22903
United States, Wisconsin
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53226
Argentina
GSK Investigational Site
Caba, Buenos Aires, Argentina, C1425DTG
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, C1426ANZ
GSK Investigational Site
Viedma, Río Negro, Argentina, R8500ACE
GSK Investigational Site
Rosario, Santa Fe, Argentina, S2000KZE
GSK Investigational Site
San Miguel de Tucumán, Argentina, T4000IAK
GSK Investigational Site
Santa Fe, Argentina, 3000
Australia, New South Wales
GSK Investigational Site
North Sydney, New South Wales, Australia, 2060
GSK Investigational Site
Westmead, New South Wales, Australia, 2145
Australia, Queensland
GSK Investigational Site
Greenslopes, Queensland, Australia, 4120
GSK Investigational Site
Herston, Queensland, Australia, 4029
GSK Investigational Site
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
GSK Investigational Site
Woodville, South Australia, Australia, 5011
Australia, Victoria
GSK Investigational Site
Box Hill, Victoria, Australia, 3128
GSK Investigational Site
Melbourne, Victoria, Australia, 3004
Australia, Western Australia
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Austria
GSK Investigational Site
Graz, Austria, A-8036
GSK Investigational Site
Innsbruck, Austria, 6020
GSK Investigational Site
Salzburg, Austria, A-5020
GSK Investigational Site
Wien, Austria, A-1030
GSK Investigational Site
Wien, Austria, 1090
Belgium
GSK Investigational Site
Brasschaat, Belgium, 2930
GSK Investigational Site
Brussels, Belgium, 1200
GSK Investigational Site
Gent, Belgium, 9000
GSK Investigational Site
Jette, Belgium, 1090
GSK Investigational Site
Kortrijk, Belgium, 8500
GSK Investigational Site
Leuven, Belgium, 3000
GSK Investigational Site
Namur, Belgium, 5000
GSK Investigational Site
Wilrijk, Belgium, 2610
Brazil
GSK Investigational Site
Ijui, Rio Grande Do Sul, Brazil, 98700-000
GSK Investigational Site
Itajaí, Santa Catarina, Brazil, 88301220
GSK Investigational Site
São Paulo - SP, Brazil, 01323-900
Canada, Alberta
GSK Investigational Site
Calgary, Alberta, Canada, T2N 4N2
Canada, British Columbia
GSK Investigational Site
Kelowna, British Columbia, Canada, V1Y 5L3
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Nova Scotia
GSK Investigational Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
GSK Investigational Site
Kingston, Ontario, Canada, K7L 5P9
GSK Investigational Site
Oshawa, Ontario, Canada, L1G 2B9
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 8L6
GSK Investigational Site
Toronto, Ontario, Canada, M5G 2M9
GSK Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
GSK Investigational Site
Montreal, Quebec, Canada, H2L 4M1
Canada
GSK Investigational Site
Quebec, Canada, G1R 2J6
Czech Republic
GSK Investigational Site
Olomouc, Czech Republic, 775 20
GSK Investigational Site
Ostrava, Czech Republic, 708 52
GSK Investigational Site
Praha 10, Czech Republic, 100 34
GSK Investigational Site
Praha 2, Czech Republic, 128 08
GSK Investigational Site
Zlin, Czech Republic, 76275
Denmark
GSK Investigational Site
Herlev, Denmark, 2730
GSK Investigational Site
Odense, Denmark, 5000 C
GSK Investigational Site
Århus C, Denmark, 8000
Finland
GSK Investigational Site
Helsinki, Finland, 00029
GSK Investigational Site
Jyvaskyla, Finland, 40620
GSK Investigational Site
Tampere, Finland, 33520
GSK Investigational Site
Turku, Finland, 20520
France
GSK Investigational Site
Bordeaux, France, 33075
GSK Investigational Site
Grenoble, France, 38043
GSK Investigational Site
Lille, France, 59037
GSK Investigational Site
Marseille cedex 5, France, 13385
GSK Investigational Site
Montpellier cedex 5, France, 34295
GSK Investigational Site
Nantes, France, 44093
GSK Investigational Site
Nice, France, 06202
GSK Investigational Site
Paris Cedex 10, France, 75475
GSK Investigational Site
Reims Cedex, France, 51092
GSK Investigational Site
Rennes Cedex, France, 35042
GSK Investigational Site
Villejuif cedex, France, 94805
Germany
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69120
GSK Investigational Site
Heilbronn, Baden-Wuerttemberg, Germany, 74078
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68167
GSK Investigational Site
Tuebingen, Baden-Wuerttemberg, Germany, 72076
GSK Investigational Site
Erlangen, Bayern, Germany, 91054
GSK Investigational Site
Muenchen, Bayern, Germany, 80337
GSK Investigational Site
Muenchen, Bayern, Germany, 80802
GSK Investigational Site
Muenchen, Bayern, Germany, 80804
GSK Investigational Site
Nuernberg, Bayern, Germany, 90419
GSK Investigational Site
Regensburg, Bayern, Germany, 93053
GSK Investigational Site
Wuerzburg, Bayern, Germany, 97080
GSK Investigational Site
Buxtehude, Niedersachsen, Germany, 21614
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53127
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45122
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50937
GSK Investigational Site
Ludwigshafen, Rheinland-Pfalz, Germany, 67063
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55131
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39120
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
GSK Investigational Site
Leipzig, Sachsen, Germany, 04103
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany, 24105
GSK Investigational Site
Luebeck, Schleswig-Holstein, Germany, 23538
GSK Investigational Site
Erfurt, Thueringen, Germany, 99089
GSK Investigational Site
Gera, Thueringen, Germany, 07548
Hungary
GSK Investigational Site
Budapest, Hungary, 1062
GSK Investigational Site
Budapest, Hungary, H-1122
GSK Investigational Site
Debrecen, Hungary, 4032
GSK Investigational Site
Győr, Hungary, H-9024
GSK Investigational Site
Kaposvár, Hungary, 7400
GSK Investigational Site
Miskolc, Hungary, 3526
GSK Investigational Site
Szeged, Hungary, 6720
Ireland
GSK Investigational Site
Co.Cork, Ireland
GSK Investigational Site
Dublin, Ireland, 7
GSK Investigational Site
Dublin, Ireland, 9
GSK Investigational Site
Dublin, Ireland, 4
GSK Investigational Site
Galway, Ireland
Israel
GSK Investigational Site
Jerusalem, Israel
GSK Investigational Site
Ramat Gan, Israel, 52621
Italy
GSK Investigational Site
Napoli, Campania, Italy, 80131
GSK Investigational Site
Roma, Lazio, Italy, 00167
GSK Investigational Site
Genova, Liguria, Italy, 16132
GSK Investigational Site
Bergamo, Lombardia, Italy, 24128
GSK Investigational Site
Milano, Lombardia, Italy, 20133
GSK Investigational Site
Milano, Lombardia, Italy, 20141
GSK Investigational Site
Pisa, Toscana, Italy, 56126
GSK Investigational Site
Padova, Veneto, Italy, 35128
Korea, Republic of
GSK Investigational Site
Goyang-si, Gyeonggi-Do, Korea, Republic of, 410-769
GSK Investigational Site
Seoul, Korea, Republic of, 135-710
GSK Investigational Site
Seoul, Korea, Republic of, 110-744
Netherlands
GSK Investigational Site
Amsterdam, Netherlands, 1066 CX
GSK Investigational Site
Amsterdam, Netherlands, 1081 HV
GSK Investigational Site
Groningen, Netherlands, 9713 GZ
GSK Investigational Site
Leeuwarden, Netherlands, 8934 AD
GSK Investigational Site
Leiden, Netherlands, 2333 ZA
GSK Investigational Site
Rotterdam, Netherlands, 3075 EA
New Zealand
GSK Investigational Site
Christchurch, New Zealand, 8011
GSK Investigational Site
Newtown, Wellington, New Zealand, 6002
Norway
GSK Investigational Site
Kristiansand, Norway, 4604
GSK Investigational Site
Lørenskog, Norway, 1478
GSK Investigational Site
Oslo, Norway, 0310
Poland
GSK Investigational Site
Gdansk, Poland, 80-215
GSK Investigational Site
Konin, Poland, 62-500
GSK Investigational Site
Poznan, Poland, 60-693
GSK Investigational Site
Warszawa, Poland, 02-781
Russian Federation
GSK Investigational Site
Chelyabinsk, Russian Federation, 454087
GSK Investigational Site
Magnitogorsk, Russian Federation, 455001
GSK Investigational Site
Moscow, Russian Federation, 115478
GSK Investigational Site
Moscow, Russian Federation, 143423
GSK Investigational Site
Nizhniy Novgorod, Russian Federation, 603081
GSK Investigational Site
Ryazan, Russian Federation, 390011
GSK Investigational Site
St. Petersburg, Russian Federation, 197758
Spain
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Hospitalet de Llobregat, Barcelona, Spain, 08907
GSK Investigational Site
Las Palmas De Gran Canaria, Spain, 35016
GSK Investigational Site
Madrid, Spain, 28050
GSK Investigational Site
Madrid, Spain, 28007
GSK Investigational Site
Palma de Mallorca, Spain, 07010
GSK Investigational Site
Pamplona, Spain, 31008
GSK Investigational Site
Valencia, Spain, 46014
GSK Investigational Site
Valencia, Spain, 46009
Sweden
GSK Investigational Site
Linköping, Sweden, SE-581 85
GSK Investigational Site
Umeå, Sweden, SE-901 85
Switzerland
GSK Investigational Site
Basel, Switzerland, 4031
GSK Investigational Site
Lausanne, Switzerland, 1011
GSK Investigational Site
Zürich, Switzerland, 8091
Taiwan
GSK Investigational Site
Tainan, Taiwan, 704
GSK Investigational Site
Taipei, Taiwan, 100
GSK Investigational Site
Taoyuan, Taiwan, 333
Ukraine
GSK Investigational Site
Dnipropetrovsk, Ukraine, 49102
GSK Investigational Site
Donetsk, Ukraine, 83092
GSK Investigational Site
Kharkiv, Ukraine, 61070
GSK Investigational Site
Kyiv, Ukraine, 03022
GSK Investigational Site
Lviv, Ukraine, 79031
GSK Investigational Site
Sumy, Ukraine, 40005
GSK Investigational Site
Uzhgorod, Ukraine, 88017
United Kingdom
GSK Investigational Site
Cambridge, United Kingdom, CB2 0QQ
GSK Investigational Site
Glasgow, United Kingdom, G12 0YN
GSK Investigational Site
London, United Kingdom, NW3 2QG
GSK Investigational Site
London, United Kingdom, SE1 7EH
GSK Investigational Site
Manchester, United Kingdom, M20 4BX
GSK Investigational Site
Southampton, United Kingdom, SO16 6YD
GSK Investigational Site
Swansea, United Kingdom, SA2 8QA
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01597908     History of Changes
Other Study ID Numbers: 116513
Study First Received: May 10, 2012
Last Updated: August 14, 2014
Health Authority: Australia: Human Research Ethics Committee
United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
BRAF inhibitor
Metastatic Melanoma
Cancer
MEK inhibitor

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Trametinib
Dabrafenib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 14, 2014